Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Finished Goods (2017 - 2024)

China Pharma Holdings (CPHI) has disclosed Finished Goods for 8 consecutive years, with $1.3 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Finished Goods rose 6.83% year-over-year to $1.3 million, compared with a TTM value of $1.3 million through Sep 2024, up 6.83%, and an annual FY2023 reading of $1.5 million, up 166.73% over the prior year.
  • Finished Goods was $1.3 million for Q3 2024 at China Pharma Holdings, down from $1.5 million in the prior quarter.
  • Across five years, Finished Goods topped out at $1.7 million in Q1 2024 and bottomed at $551000.0 in Q4 2021.
  • Average Finished Goods over 5 years is $1.2 million, with a median of $1.3 million recorded in 2022.
  • The sharpest move saw Finished Goods tumbled 46.0% in 2021, then skyrocketed 166.73% in 2023.
  • Year by year, Finished Goods stood at $960375.0 in 2020, then crashed by 42.63% to $551000.0 in 2021, then changed by 0.0% to $551000.0 in 2022, then soared by 166.73% to $1.5 million in 2023, then decreased by 11.91% to $1.3 million in 2024.
  • Business Quant data shows Finished Goods for CPHI at $1.3 million in Q3 2024, $1.5 million in Q2 2024, and $1.7 million in Q1 2024.